Terms: = Head and neck cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Clinical Outcome
9 results:
1. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of Combined vegfr1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric cancer.
Won E; Basunia A; Chatila WK; Hechtman JF; Chou JF; Ku GY; Chalasani SB; Boyar MS; Goldberg Z; Desai AM; Tuvy Y; Berger MF; Tang L; Kelsen DP; Schattner M; Ilson DH; Capanu M; Solit DB; Schultz N; Janjigian YY
Clin Cancer Res; 2019 Jul; 25(13):3811-3817. PubMed ID: 30952642
[TBL] [Abstract] [Full Text] [Related]
3. Immunoexpression of vegfr-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
de Aquino AR; Nonaka CF; de Carvalho CH; Demeda CF; de Souza LB; Pinto LP
Int J Oral Maxillofac Surg; 2017 Jan; 46(1):16-23. PubMed ID: 27745792
[TBL] [Abstract] [Full Text] [Related]
4. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract] [Full Text] [Related]
5. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract] [Full Text] [Related]
6. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract] [Full Text] [Related]
7. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
Tsirlis TD; Papastratis G; Masselou K; Tsigris C; Papachristodoulou A; Kostakis A; Nikiteas NI
World J Gastroenterol; 2008 May; 14(17):2691-701. PubMed ID: 18461654
[TBL] [Abstract] [Full Text] [Related]
8. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.
Jebreel A; England J; Bedford K; Murphy J; Karsai L; Atkin S
Int J Exp Pathol; 2007 Aug; 88(4):271-7. PubMed ID: 17696908
[TBL] [Abstract] [Full Text] [Related]
9. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract] [Full Text] [Related]
